| |
| |
|
| Insider
Information: |
Stalfort Sean |
| Relationship: |
Director |
| City: |
Charlottesville |
| State: |
VA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,921,910 |
|
|
Indirect Shares
|
1,015,885 |
|
|
| Direct
Value |
$4,754,392 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,937,795 |
|
|
| Total
Value |
$4,754,392 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
3.0
|
0.0
|
| Percentage
Gain/Loss : |
 105.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dova Pharmaceuticals, Inc. |
DOVA |
Director |
2019-11-12 |
0 |
|
0 |
Premium* |
|
|
Verrica Pharmaceuticals Inc. |
VRCA |
Director |
2022-07-05 |
700,205 |
2018-06-19 |
0 |
Premium* |
|
|
Acumen Pharmaceuticals, Inc. |
ABOS |
Director |
2021-07-06 |
172,324 |
2021-07-06 |
131,595 |
Premium* |
|
|
Taysha Gene Therapies, Inc. |
TSHA |
Director |
2023-08-16 |
1,049,381 |
2023-08-16 |
884,290 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • – |
2023-08-16 |
4 |
GA |
$0.00 |
$0 |
D/D |
50,000 |
1,049,381 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • – |
2023-08-16 |
4 |
B |
$0.90 |
$350,000 |
D/D |
388,889 |
999,381 |
2.39 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • – |
2023-08-16 |
4 |
B |
$0.90 |
$350,000 |
I/I |
388,889 |
884,290 |
2.1 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • – |
2023-06-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
495,401 |
|
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • – |
2023-06-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
610,492 |
|
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • – |
2022-07-05 |
4 |
B |
$2.10 |
$500,000 |
D/D |
238,095 |
700,205 |
2.39 |
% |
|
| ABOS |
Acumen Pharmaceuticals, I... |
Director |
– • – |
2021-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
131,595 |
131,595 |
0 |
- |
|
| ABOS |
Acumen Pharmaceuticals, I... |
Director |
– • – |
2021-07-06 |
4 |
B |
$16.00 |
$560,000 |
D/D |
35,000 |
172,324 |
2.39 |
- |
|
| ABOS |
Acumen Pharmaceuticals, I... |
Director |
– • – |
2021-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
130,180 |
137,324 |
0 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • – |
2020-08-14 |
4 |
B |
$6.38 |
$100,166 |
D/D |
15,700 |
462,110 |
2.39 |
% |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • – |
2020-08-13 |
4 |
B |
$6.45 |
$100,298 |
D/D |
15,550 |
446,410 |
2.39 |
% |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • – |
2019-11-12 |
4 |
D |
$27.50 |
$17,480,788 |
D/D |
(635,665) |
0 |
0 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • – |
2019-01-07 |
4 |
B |
$10.38 |
$96,386 |
D/D |
9,221 |
430,860 |
2.39 |
- |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • – |
2018-12-20 |
4 |
B |
$6.26 |
$194,060 |
D/D |
31,000 |
635,665 |
2.39 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • – |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
394,295 |
421,639 |
0 |
- |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • – |
2017-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
604,665 |
|
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
